Recent News

• 04.09.2025 - Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
• 02.25.2025 - Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
• 02.13.2025 - Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
• 02.10.2025 - Grace Therapeutics Announces Private Placement Financing of up to $30 Million
• 02.10.2025 - Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
• 01.07.2025 - Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Recent Filings

• 04.09.2025 - EX-99.1 EX-99.1
• 04.09.2025 - 8-K Current report
• 03.13.2025 - EFFECT Notice of Effectiveness
• 03.10.2025 - S-3 Registration statement under Securities Act of 1933
• 03.03.2025 - 8-K Current report
• 03.03.2025 - EX-99.1 EX-99.1
• 02.25.2025 - D Notice of Exempt Offering of Securities
• 02.19.2025 - 10-Q/A Quarterly report [Sections 13 or 15(d)]
• 02.13.2025 - 8-K Current report
• 02.13.2025 - EX-99.1 EX-99.1